Literature DB >> 19542537

CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3.

Thorsten Mueller1, Peter Breuer, Ina Schmitt, Jochen Walter, Bernd O Evert, Ullrich Wüllner.   

Abstract

The nuclear presence of the expanded disease proteins is of critical importance for the pathogeneses of polyglutamine diseases. Here we show that protein casein kinase 2 (CK2)-dependent phosphorylation controls the nuclear localization, aggregation and stability of ataxin-3 (ATXN3), the disease protein in spinocerebellar ataxia type 3 (SCA3). Serine 340 and 352 within the third ubiquitin-interacting motif of ATXN3 were particularly important for nuclear localization of normal and expanded ATXN3 and mutation of these sites robustly reduced the formation of nuclear inclusions; a putative nuclear leader sequence was not required. ATXN3 associated with CK2alpha and pharmacological inhibition of CK2 decreased nuclear ATXN3 levels and the formation of nuclear inclusions. Moreover, we found that ATXN3 shifted to the nucleus upon thermal stress in a CK2-dependent manner, indicating a key role of CK2-mediated phosphorylation of ATXN3 in SCA3 pathophysiology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19542537     DOI: 10.1093/hmg/ddp274

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  38 in total

Review 1.  Toward understanding Machado-Joseph disease.

Authors:  Maria do Carmo Costa; Henry L Paulson
Journal:  Prog Neurobiol       Date:  2011-11-23       Impact factor: 11.685

2.  Nuclear aggregation of polyglutamine-expanded ataxin-3: fragments escape the cytoplasmic quality control.

Authors:  Peter Breuer; Annette Haacke; Bernd O Evert; Ullrich Wüllner
Journal:  J Biol Chem       Date:  2010-01-11       Impact factor: 5.157

3.  Therapeutic prospects for spinocerebellar ataxia type 2 and 3.

Authors:  Ilya Bezprozvanny; Thomas Klockgether
Journal:  Drugs Future       Date:  2009-12       Impact factor: 0.148

4.  Phosphorylation of bovine papillomavirus E1 by the protein kinase CK2 near the nuclear localization signal does not influence subcellular distribution of the protein in dividing cells.

Authors:  Michael R Lentz; Tess Shideler
Journal:  Arch Virol       Date:  2015-10-14       Impact factor: 2.574

Review 5.  Spinocerebellar ataxia type 2: clinical presentation, molecular mechanisms, and therapeutic perspectives.

Authors:  J J Magaña; L Velázquez-Pérez; B Cisneros
Journal:  Mol Neurobiol       Date:  2012-09-21       Impact factor: 5.590

6.  Kinase inhibitors modulate huntingtin cell localization and toxicity.

Authors:  Randy Singh Atwal; Carly R Desmond; Nicholas Caron; Tamara Maiuri; Jianrun Xia; Simonetta Sipione; Ray Truant
Journal:  Nat Chem Biol       Date:  2011-05-29       Impact factor: 15.040

7.  Physiological and pathophysiological characteristics of ataxin-3 isoforms.

Authors:  Daniel Weishäupl; Juliane Schneider; Barbara Peixoto Pinheiro; Corinna Ruess; Sandra Maria Dold; Felix von Zweydorf; Christian Johannes Gloeckner; Jana Schmidt; Olaf Riess; Thorsten Schmidt
Journal:  J Biol Chem       Date:  2018-11-19       Impact factor: 5.157

8.  Splice isoforms of the polyglutamine disease protein ataxin-3 exhibit similar enzymatic yet different aggregation properties.

Authors:  Ginny Marie Harris; Katerina Dodelzon; Lijie Gong; Pedro Gonzalez-Alegre; Henry L Paulson
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

9.  Proteotoxic stress increases nuclear localization of ataxin-3.

Authors:  Christopher P Reina; Xiaoyan Zhong; Randall N Pittman
Journal:  Hum Mol Genet       Date:  2009-10-19       Impact factor: 6.150

10.  Karyopherin α-3 is a key protein in the pathogenesis of spinocerebellar ataxia type 3 controlling the nuclear localization of ataxin-3.

Authors:  Anna Sergeevna Sowa; Elodie Martin; Inês Morgado Martins; Jana Schmidt; Reinhard Depping; Jonasz Jeremiasz Weber; Franziska Rother; Enno Hartmann; Michael Bader; Olaf Riess; Hervé Tricoire; Thorsten Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.